866-997-4948(US-Canada Toll Free)

Obesity - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Metabolic Disorders

No. of Pages : 562 Pages

This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Obesity
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Obesity and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Obesity pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Obesity
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
Introduction 8
Obesity Overview 9
Therapeutics Development 10
Obesity - Therapeutics under Development by Companies 12
Obesity - Therapeutics under Investigation by Universities/Institutes 22
Obesity - Pipeline Products Glance 26
Obesity - Products under Development by Companies 30
Obesity - Products under Investigation by Universities/Institutes 42
Obesity - Companies Involved in Therapeutics Development 45
Obesity - Therapeutics Assessment 151
Drug Profiles 178
Obesity - Recent Pipeline Updates 452
Obesity - Dormant Projects 510
Obesity - Discontinued Products 522
Obesity - Product Development Milestones 528

Appendix 536

List of Table


Number of Products under Development for Obesity, H1 2014 35
Number of Products under Development for Obesity - Comparative Analysis, H1 2014 36
Number of Products under Development by Companies, H1 2014 38
Number of Products under Development by Companies, H1 2014 (Contd..1) 39
Number of Products under Development by Companies, H1 2014 (Contd..2) 40
Number of Products under Development by Companies, H1 2014 (Contd..3) 41
Number of Products under Development by Companies, H1 2014 (Contd..4) 42
Number of Products under Development by Companies, H1 2014 (Contd..5) 43
Number of Products under Development by Companies, H1 2014 (Contd..6) 44
Number of Products under Development by Companies, H1 2014 (Contd..7) 45
Number of Products under Development by Companies, H1 2014 (Contd..8) 46
Number of Products under Investigation by Universities/Institutes, H1 2014 48
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 49
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 50
Comparative Analysis by Late Stage Development, H1 2014 51
Comparative Analysis by Clinical Stage Development, H1 2014 52
Comparative Analysis by Early Stage Development, H1 2014 53
Comparative Analysis by Unknown Stage Development, H1 2014 54
Products under Development by Companies, H1 2014 55
Products under Development by Companies, H1 2014 (Contd..1) 56
Products under Development by Companies, H1 2014 (Contd..2) 57
Products under Development by Companies, H1 2014 (Contd..3) 58
Products under Development by Companies, H1 2014 (Contd..4) 59
Products under Development by Companies, H1 2014 (Contd..5) 60
Products under Development by Companies, H1 2014 (Contd..6) 61
Products under Development by Companies, H1 2014 (Contd..7) 62
Products under Development by Companies, H1 2014 (Contd..8) 63
Products under Development by Companies, H1 2014 (Contd..9) 64
Products under Development by Companies, H1 2014 (Contd..10) 65
Products under Development by Companies, H1 2014 (Contd..11) 66
Products under Investigation by Universities/Institutes, H1 2014 67
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 68
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 69
Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 70
Obesity - Pipeline by Shionogi & Co., Ltd., H1 2014 71
Obesity - Pipeline by Amgen Inc., H1 2014 72
Obesity - Pipeline by Sanofi, H1 2014 73
Obesity - Pipeline by AstraZeneca PLC, H1 2014 74
Obesity - Pipeline by Eli Lilly and Company, H1 2014 75
Obesity - Pipeline by Athersys, Inc., H1 2014 76
Obesity - Pipeline by GlaxoSmithKline plc, H1 2014 77
Obesity - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 78
Obesity - Pipeline by Merck & Co., Inc., H1 2014 79
Obesity - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 80
Obesity - Pipeline by Euroscreen S.A., H1 2014 81
Obesity - Pipeline by Novo Nordisk A/S, H1 2014 82
Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 83
Obesity - Pipeline by Plexxikon Inc., H1 2014 84
Obesity - Pipeline by Ipsen S.A., H1 2014 85
Obesity - Pipeline by CARDIONOVA LTD., H1 2014 86
Obesity - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2014 87
Obesity - Pipeline by GTx, Inc., H1 2014 88
Obesity - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014 89
Obesity - Pipeline by LEO Pharma A/S, H1 2014 90
Obesity - Pipeline by Pfizer Inc., H1 2014 91
Obesity - Pipeline by Vivus, Inc., H1 2014 92
Obesity - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 93
Obesity - Pipeline by OPKO Health, Inc., H1 2014 94
Obesity - Pipeline by Genfit SA, H1 2014 95
Obesity - Pipeline by Arrowhead Research Corporation, H1 2014 96
Obesity - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 97
Obesity - Pipeline by Calzada Limited, H1 2014 98
Obesity - Pipeline by NeuroSearch A/S, H1 2014 99
Obesity - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2014 100
Obesity - Pipeline by Arena Pharmaceuticals, Inc., H1 2014 101
Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2014 102
Obesity - Pipeline by Handok Inc., H1 2014 103
Obesity - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2014 104
Obesity - Pipeline by LG Life Sciences, Ltd., H1 2014 105
Obesity - Pipeline by Transition Therapeutics Inc., H1 2014 106
Obesity - Pipeline by Suven Life Sciences Ltd., H1 2014 107
Obesity - Pipeline by Galapagos NV, H1 2014 108
Obesity - Pipeline by Phynova Group Ltd, H1 2014 109
Obesity - Pipeline by Orexigen Therapeutics, Inc., H1 2014 110
Obesity - Pipeline by DiaMedica Inc., H1 2014 111
Obesity - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 112
Obesity - Pipeline by Digna Biotech, S.L., H1 2014 113
Obesity - Pipeline by Advinus Therapeutics Ltd., H1 2014 114
Obesity - Pipeline by Betagenon AB, H1 2014 115
Obesity - Pipeline by Aurigene Discovery Technologies Limited, H1 2014 116
Obesity - Pipeline by Jenrin Discovery, Inc., H1 2014 117
Obesity - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 118
Obesity - Pipeline by ObeTherapy Biotechnology, H1 2014 119
Obesity - Pipeline by Helsinn Healthcare S.A., H1 2014 120
Obesity - Pipeline by Xenon Pharmaceuticals Inc., H1 2014 121
Obesity - Pipeline by Spherix Incorporated, H1 2014 122
Obesity - Pipeline by Ocera Therapeutics, Inc., H1 2014 123
Obesity - Pipeline by AngioChem Inc., H1 2014 124
Obesity - Pipeline by Kedem Pharmaceuticals Inc., H1 2014 125
Obesity - Pipeline by Zafgen Inc., H1 2014 126
Obesity - Pipeline by Ambrx, Inc., H1 2014 127
Obesity - Pipeline by Braasch Biotech LLC, H1 2014 128
Obesity - Pipeline by Zealand Pharma A/S, H1 2014 129
Obesity - Pipeline by Indus Biotech Private Limited, H1 2014 130
Obesity - Pipeline by Intarcia Therapeutics, Inc., H1 2014 131
Obesity - Pipeline by Thrasos, Inc., H1 2014 132
Obesity - Pipeline by Versartis, Inc., H1 2014 133
Obesity - Pipeline by Kainos Medicine, Inc., H1 2014 134
Obesity - Pipeline by Nordic Bioscience a/s, H1 2014 135
Obesity - Pipeline by Avaxia Biologics, Inc., H1 2014 136
Obesity - Pipeline by Omeros Corporation, H1 2014 137
Obesity - Pipeline by Aegis Therapeutics, LLC, H1 2014 138
Obesity - Pipeline by Bridge Bioresearch Plc, H1 2014 139
Obesity - Pipeline by Globeimmune, Inc., H1 2014 141
Obesity - Pipeline by Targacept, Inc., H1 2014 142
Obesity - Pipeline by Molecular Design International, Inc., H1 2014 143
Obesity - Pipeline by N-Gene Research Laboratories, Inc., H1 2014 144
Obesity - Pipeline by Seek, H1 2014 145
Obesity - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 146
Obesity - Pipeline by Galenea Corp., H1 2014 147
Obesity - Pipeline by Verva Pharmaceuticals Limited, H1 2014 148
Obesity - Pipeline by Regulus Therapeutics Inc., H1 2014 149
Obesity - Pipeline by Esperion Therapeutics, Inc., H1 2014 150
Obesity - Pipeline by Sorrento Therapeutics, Inc., H1 2014 151
Obesity - Pipeline by Domainex Ltd., H1 2014 152
Obesity - Pipeline by Alize Pharma SAS, H1 2014 153
Obesity - Pipeline by DiscoveryBiomed, Inc., H1 2014 154
Obesity - Pipeline by Mitsubishi Pharmaceutical Corporation, H1 2014 155
Obesity - Pipeline by Sirona Biochem Corp, H1 2014 156
Obesity - Pipeline by Vicore Pharma AB, H1 2014 157
Obesity - Pipeline by Carmot Therapeutics, Inc., H1 2014 158
Obesity - Pipeline by Reviva Pharmaceuticals Inc., H1 2014 159
Obesity - Pipeline by PharmaIN Corporation, H1 2014 160
Obesity - Pipeline by Rhythm Pharmaceuticals, H1 2014 161
Obesity - Pipeline by Selvita S.A, H1 2014 162
Obesity - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 163
Obesity - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, H1 2014 164
Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 165
Obesity - Pipeline by X-BODY BioSciences, Inc., H1 2014 166
Obesity - Pipeline by Lead Discovery Center GmbH, H1 2014 167
Obesity - Pipeline by Adial Pharmaceuticals, LLC, H1 2014 168
Obesity - Pipeline by P2D Bioscience, H1 2014 169
Obesity - Pipeline by High Point Pharmaceuticals, LLC, H1 2014 170
Obesity - Pipeline by Arrien Pharmaceuticals, LLC, H1 2014 171
Obesity - Pipeline by Chronos Therapeutics Limited, H1 2014 172
Obesity - Pipeline by nLife Therapeutics, S.L., H1 2014 173
Obesity - Pipeline by XL-protein GmbH, H1 2014 174
Obesity - Pipeline by Akron Molecules GmbH, H1 2014 175
Assessment by Monotherapy Products, H1 2014 176
Assessment by Combination Products, H1 2014 177
Number of Products by Stage and Target, H1 2014 180
Number of Products by Stage and Mechanism of Action, H1 2014 190
Number of Products by Stage and Route of Administration, H1 2014 199
Number of Products by Stage and Molecule Type, H1 2014 202
Obesity Therapeutics - Recent Pipeline Updates, H1 2014 477
Obesity - Dormant Projects, H1 2014 535
Obesity - Dormant Projects (Contd..1), H1 2014 536
Obesity - Dormant Projects (Contd..2), H1 2014 537
Obesity - Dormant Projects (Contd..3), H1 2014 538
Obesity - Dormant Projects (Contd..4), H1 2014 539
Obesity - Dormant Projects (Contd..5), H1 2014 540
Obesity - Dormant Projects (Contd..6), H1 2014 541
Obesity - Dormant Projects (Contd..7), H1 2014 542
Obesity - Dormant Projects (Contd..8), H1 2014 543
Obesity - Dormant Projects (Contd..9), H1 2014 544
Obesity - Dormant Projects (Contd..10), H1 2014 545
Obesity - Dormant Projects (Contd..11), H1 2014 546
Obesity - Discontinued Products, H1 2014 547
Obesity - Discontinued Products (Contd..1), H1 2014 548
Obesity - Discontinued Products (Contd..2), H1 2014 549
Obesity - Discontinued Products (Contd..3), H1 2014 550
Obesity - Discontinued Products (Contd..4), H1 2014 551
Obesity - Discontinued Products (Contd..5), H1 2014 552

List of Chart


Number of Products under Development for Obesity, H1 2014 35
Number of Products under Development for Obesity - Comparative Analysis, H1 2014 36
Number of Products under Development by Companies, H1 2014 37
Number of Products under Investigation by Universities/Institutes, H1 2014 47
Comparative Analysis by Late Stage Development, H1 2014 51
Comparative Analysis by Clinical Stage Development, H1 2014 52
Comparative Analysis by Early Stage Products, H1 2014 53
Assessment by Monotherapy Products, H1 2014 176
Assessment by Combination Products, H1 2014 177
Number of Products by Top 10 Target, H1 2014 178
Number of Products by Stage and Top 10 Target, H1 2014 179
Number of Products by Top 10 Mechanism of Action, H1 2014 188
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 189
Number of Products by Top 10 Route of Administration, H1 2014 197
Number of Products by Stage and Top 10 Route of Administration, H1 2014 198
Number of Products by Top 10 Molecule Type, H1 2014 200
Number of Products by Stage and Top 10 Molecule Type, H1 2014 201

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *